ML-9

ML-9

• CAS Number: 105637-50-1
• UNSPSC Description: ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54?μM, respectively[1]. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation[3].
• Target Antigen: Myosin
• Type: Reference compound
• Related Pathways: Cytoskeleton
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/ml-9.html
• Purity: 99.86
• Solubility: DMSO : 83.33 mg/mL (ultrasonic)|H2O : ≥ 5 mg/mL
• Smiles: O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O.[H]Cl
• Molecular Weight: 361.29
• References & Citations: [1]Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis.Eur J Pharmacol. 2004 Feb 23;486(3):325-33.|[2]Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content.Toxicol In Vitro. 2018 Apr;48:121-127.|[3]Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.Cell Death Dis. 2014 Apr 24;5:e1193.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported